ONL1204 is a novel, first-in-class small molecule peptide designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and
Prostate cancer is the second most common cancer in men, impacting more than 14 million patients worldwide. The disease has long been underrepresented at the preclinical modeling stage
RedHill further announced the submission to the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) protocol for the Phase II clinical study with BEKINDA
Amarantus published positive results from a Phase 2 initial proof-of-concept clinical study in February of 2015 in the journal Brain, and highlighted the publication of two independent peer-reviewed
This relationship will leverage Lonza’s expertise for the development of a cost-effective, scalable and robust suspension culture-based adenovirus manufacturing platform, which is anticipated to enable the production of
The FDA has agreed with Cellceutix’s plan to initiate such a trial, and based upon the data from the Phase 1 trial, that the administration of Kevetrin doses
The revefenacin Phase 3 program, which includes two replicate efficacy studies and a single twelve-month long-term safety study, is designed to support the registration of the product in
The agency sent a complete response letter to Vertex, stating that it cannot approve the company’s supplemental new drug application (sNDA) in its current form. Vertex plans to
The milestone was triggered by Takeda surpassing annual ADCETRIS net sales of $200m in its territory during 2015. The milestone will be recognized as royalty revenue in the
This clinical trial is an open label dose-escalation and expansion study designed to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), tolerability, pharmacokinetics and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.